PARP inhibitors in BRCA mutation-associated ovarian cancer

被引：22
|
作者：
Clamp, Andrew [1 ]
Jayson, Gordon
机构：
[1] Christie, Inst Canc Sci, Manchester M20 4BX, Lancs, England
来源：
LANCET ONCOLOGY | 2015年 / 16卷 / 01期
关键词：
OLAPARIB MAINTENANCE THERAPY; RANDOMIZED PHASE-2; POLYMERASE;
D O I：
10.1016/S1470-2045(14)71172-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：10 / 12
页数：4
相关论文
共 50 条
  • [1] Beyond breast and ovarian cancers: PARP BRCA mutation-associated and BRCA-like inhibitors for solid tumors
    O'Sullivan, Clara C.
    Moon, Dominic H.
    Kohn, Elise C.
    Lee, Jung-Mim
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [2] PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
    Lee, J-m.
    Ledermann, J. A.
    Kohn, E. C.
    ANNALS OF ONCOLOGY, 2014, 25 (01) : 32 - 40
  • [3] Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer
    Domchek, Susan M.
    Jhaveri, Komal
    Patil, Sujata
    Stopfer, Jill E.
    Hudis, Clifford
    Powers, Jacquelyn
    Stadler, Zsofia
    Goldstein, Laura
    Kauff, Noah
    Khasraw, Mustafa
    Offit, Kenneth
    Nathanson, Katherine L.
    Robson, Mark
    CANCER, 2013, 119 (07) : 1344 - 1348
  • [4] Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer
    Gupta, Tanya
    Vinayak, Shaveta
    Telli, Melinda
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 197 (01) : 51 - 56
  • [5] Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer
    Tanya Gupta
    Shaveta Vinayak
    Melinda Telli
    Breast Cancer Research and Treatment, 2023, 197 : 51 - 56
  • [6] Systemic therapy options in BRCA mutation-associated breast cancer
    Bayraktar, Soley
    Glueck, Stefan
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 135 (02) : 355 - 366
  • [7] Systemic therapy options in BRCA mutation-associated breast cancer
    Soley Bayraktar
    Stefan Glück
    Breast Cancer Research and Treatment, 2012, 135 : 355 - 366
  • [8] Parp inhibitors for brca1/2mutation associated breast cancer
    Tutt, A. N. J.
    CANCER RESEARCH, 2022, 82 (04)
  • [9] BRCA Mutations and PARP Inhibitors in Breast and/or Ovarian Cancer Patients
    Gari, Abdulrahim
    Rawas, Ghufran
    Mufti, Ahmad
    Elemam, Omima
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND ALLIED SCIENCES, 2021, 10 (03): : 33 - 49
  • [10] PARP inhibitors for hereditary breast cancer with germline BRCA mutation
    Im, Seock-Ah
    ANNALS OF ONCOLOGY, 2022, 33 : S423 - S423
12345